SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Company Announcement: SAB BIO, a clinical-stage biopharmaceutical company, will have its Chairman and CEO Samuel J. Reich speaking at the 2024 Guggenheim Securities Healthcare Innovation Conference in Boston on November 11, 2024.
Company Focus: SAB BIO is developing human anti-thymocyte immunoglobulin (hIgG) aimed at delaying the onset or progression of type 1 diabetes, utilizing advanced genetic engineering to create high-potency immunoglobulins without needing human donors.
Trade with 70% Backtested Accuracy
Analyst Views on SABS
About SABS
About the author
SAB Biotherapeutics Promotes SAB-142 for Type 1 Diabetes at Oppenheimer Conference
- Trial Design: SAB-142 is being evaluated in the global Phase IIb SAFEGUARD trial targeting newly diagnosed Stage 3 T1D patients with dosing every six months across three arms (2.5 mg/kg, 1.5 mg/kg, and placebo), with a primary endpoint of C-peptide at one year, aiming for last patient in by end-2026 and top-line data in H2 2027.
- Market Potential: SAB identifies an initial addressable market of approximately 64,000 new Stage 3 diagnoses annually in the U.S., and with Tzield priced at $200,000, SAB-142 presents a significant market opportunity, especially as redosing could expand commercial prospects to meet urgent patient needs.
- Financial Position: Ending 2025 with $140 million in cash, SAB is well-positioned to fund the SAFEGUARD trial through top-line readout and into 2028, ensuring adequate financial resources during critical development phases.
- Technical Advantages: As a fully human anti-thymocyte globulin, SAB-142 avoids the serum sickness and anti-drug antibody issues associated with rabbit ATG, offering better tolerability and redosing capabilities, aimed at inducing T-cell exhaustion to protect pancreatic beta cells and enhance insulin production in patients.
SAB Biotherapeutics Advances SAB-142 Clinical Trial for Stage 3 Diabetes Treatment Following Positive Phase 1 Results
- Safety Confirmation: The Phase 1 trial involving 62 healthy volunteers and 6 T1D patients demonstrated that SAB-142 did not cause serum sickness or any drug-related serious adverse events, indicating a strong safety profile that could position it as a new treatment option for diabetes.
- Dosing Flexibility: SAB-142 showed good tolerability across various doses (0.03-4.5mg/kg), and lymphopenia observed after dosing corrected rapidly within 1-3 days, highlighting its potential for safe redosing in patients.
- Clinical Advancement: Following positive Phase 1 results, SAB Biotherapeutics has initiated the Phase 2b SAFEGUARD trial, set to recruit patients at multiple global sites, with plans to dose the first patient by year-end, further assessing its efficacy in new-onset stage 3 diabetes patients.
- Market Potential: As a potentially disease-modifying immunotherapy, SAB-142 aims to delay the progression of T1D, addressing the urgent need for novel diabetes treatment options and potentially transforming the treatment landscape in this field.
SAB Biotherapeutics Confirms SAB-142 Safety, Advances to Phase 2b Clinical Trial
- Safety Confirmation: The Phase 1 trial of SAB-142 involving 62 healthy volunteers and 6 T1D patients demonstrated no serum sickness or immunogenicity, with no drug-related serious adverse events reported, indicating a safety profile superior to traditional treatments.
- Clinical Advancement: Following positive Phase 1 results, SAB-142 has advanced to the registrational Phase 2b SAFEGUARD trial aimed at evaluating its efficacy in new-onset stage 3 T1D patients, with dosing expected to commence by year-end.
- Dosing Flexibility: The drug exhibited good tolerability after multiple doses without sustained lymphopenia, showcasing its potential for safe redosing, which could transform the treatment paradigm for T1D.
- Global Recruitment: The SAFEGUARD trial is actively recruiting patients at multiple sites worldwide, as SAB Biotherapeutics aims to provide new treatment options for T1D patients, addressing the urgent market demand for effective therapies.
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates
Initiation of SAFEGUARD Trial: SAB Biotherapeutics has launched the registrational Phase 2b SAFEGUARD trial for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, with plans to dose the first patient by year-end.
Clinical Data Presentation: Recent presentations at EASD and ISPAD highlighted the favorable safety profile and multi-specific mechanism of action of SAB-142, reinforcing its potential as a disease-modifying treatment for T1D.
Financial Position: As of September 30, 2025, SAB Biotherapeutics reported a strong cash position of $161.5 million, enabling continued investment in the SAB-142 program and other research activities.
Upcoming Milestones: The company is on track to share additional data from the SAFEGUARD trial in the second half of 2027 and finalize Phase 1 study results by the end of this year.
SAB BIO Showcases Data Through Various Presentations at EASD
SAB-142 Phase 2b Study Initiation: SAB Biotherapeutics has launched its Phase 2b SAFEGUARD study for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, and engaged with T1D thought leaders at the EASD Annual Meeting.
Validation of SAB-142's Efficacy: Presentations at EASD highlighted SAB-142's potential as a best-in-class immunotherapy for T1D, demonstrating a clinically validated mechanism of action and favorable pharmacokinetic profile, while also confirming the disease-modifying effects of rabbit ATG in a related study.
Leerink Partners Begins Coverage of SAB Biotherapeutics (SABS) with a Positive Outlook
Coverage Initiation: Leerink Partners initiated coverage of SAB Biotherapeutics with an "Outperform" recommendation, projecting a significant upside of 336.47% based on an average one-year price target of $9.38/share.
Fund Sentiment: There has been a slight decrease in institutional ownership, with 34 funds reporting positions in SAB Biotherapeutics, while total shares owned by institutions decreased by 12.93% over the last three months.
SAB Biotherapeutics Promotes SAB-142 for Type 1 Diabetes at Oppenheimer Conference
- Trial Design: SAB-142 is being evaluated in the global Phase IIb SAFEGUARD trial targeting newly diagnosed Stage 3 T1D patients with dosing every six months across three arms (2.5 mg/kg, 1.5 mg/kg, and placebo), with a primary endpoint of C-peptide at one year, aiming for last patient in by end-2026 and top-line data in H2 2027.
- Market Potential: SAB identifies an initial addressable market of approximately 64,000 new Stage 3 diagnoses annually in the U.S., and with Tzield priced at $200,000, SAB-142 presents a significant market opportunity, especially as redosing could expand commercial prospects to meet urgent patient needs.
- Financial Position: Ending 2025 with $140 million in cash, SAB is well-positioned to fund the SAFEGUARD trial through top-line readout and into 2028, ensuring adequate financial resources during critical development phases.
- Technical Advantages: As a fully human anti-thymocyte globulin, SAB-142 avoids the serum sickness and anti-drug antibody issues associated with rabbit ATG, offering better tolerability and redosing capabilities, aimed at inducing T-cell exhaustion to protect pancreatic beta cells and enhance insulin production in patients.
SAB Biotherapeutics Advances SAB-142 Clinical Trial for Stage 3 Diabetes Treatment Following Positive Phase 1 Results
- Safety Confirmation: The Phase 1 trial involving 62 healthy volunteers and 6 T1D patients demonstrated that SAB-142 did not cause serum sickness or any drug-related serious adverse events, indicating a strong safety profile that could position it as a new treatment option for diabetes.
- Dosing Flexibility: SAB-142 showed good tolerability across various doses (0.03-4.5mg/kg), and lymphopenia observed after dosing corrected rapidly within 1-3 days, highlighting its potential for safe redosing in patients.
- Clinical Advancement: Following positive Phase 1 results, SAB Biotherapeutics has initiated the Phase 2b SAFEGUARD trial, set to recruit patients at multiple global sites, with plans to dose the first patient by year-end, further assessing its efficacy in new-onset stage 3 diabetes patients.
- Market Potential: As a potentially disease-modifying immunotherapy, SAB-142 aims to delay the progression of T1D, addressing the urgent need for novel diabetes treatment options and potentially transforming the treatment landscape in this field.
SAB Biotherapeutics Confirms SAB-142 Safety, Advances to Phase 2b Clinical Trial
- Safety Confirmation: The Phase 1 trial of SAB-142 involving 62 healthy volunteers and 6 T1D patients demonstrated no serum sickness or immunogenicity, with no drug-related serious adverse events reported, indicating a safety profile superior to traditional treatments.
- Clinical Advancement: Following positive Phase 1 results, SAB-142 has advanced to the registrational Phase 2b SAFEGUARD trial aimed at evaluating its efficacy in new-onset stage 3 T1D patients, with dosing expected to commence by year-end.
- Dosing Flexibility: The drug exhibited good tolerability after multiple doses without sustained lymphopenia, showcasing its potential for safe redosing, which could transform the treatment paradigm for T1D.
- Global Recruitment: The SAFEGUARD trial is actively recruiting patients at multiple sites worldwide, as SAB Biotherapeutics aims to provide new treatment options for T1D patients, addressing the urgent market demand for effective therapies.
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates
Initiation of SAFEGUARD Trial: SAB Biotherapeutics has launched the registrational Phase 2b SAFEGUARD trial for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, with plans to dose the first patient by year-end.
Clinical Data Presentation: Recent presentations at EASD and ISPAD highlighted the favorable safety profile and multi-specific mechanism of action of SAB-142, reinforcing its potential as a disease-modifying treatment for T1D.
Financial Position: As of September 30, 2025, SAB Biotherapeutics reported a strong cash position of $161.5 million, enabling continued investment in the SAB-142 program and other research activities.
Upcoming Milestones: The company is on track to share additional data from the SAFEGUARD trial in the second half of 2027 and finalize Phase 1 study results by the end of this year.
SAB BIO Showcases Data Through Various Presentations at EASD
SAB-142 Phase 2b Study Initiation: SAB Biotherapeutics has launched its Phase 2b SAFEGUARD study for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, and engaged with T1D thought leaders at the EASD Annual Meeting.
Validation of SAB-142's Efficacy: Presentations at EASD highlighted SAB-142's potential as a best-in-class immunotherapy for T1D, demonstrating a clinically validated mechanism of action and favorable pharmacokinetic profile, while also confirming the disease-modifying effects of rabbit ATG in a related study.
Leerink Partners Begins Coverage of SAB Biotherapeutics (SABS) with a Positive Outlook
Coverage Initiation: Leerink Partners initiated coverage of SAB Biotherapeutics with an "Outperform" recommendation, projecting a significant upside of 336.47% based on an average one-year price target of $9.38/share.
Fund Sentiment: There has been a slight decrease in institutional ownership, with 34 funds reporting positions in SAB Biotherapeutics, while total shares owned by institutions decreased by 12.93% over the last three months.
